Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016
Published Jun 22, 2016
158 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-

  
Source:
Document ID
GMDHC0269TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview121
Therapeutics Development135
  Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Stage of Development131
  Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Therapy Area141
  Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Indication153
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Pipeline Products Glance182
  Late Stage Products181
  Early Stage Products191
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Companies209
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Products under Development by Universities/Institutes292
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Therapeutics Assessment316
  Assessment by Monotherapy/Combination Products311
  Assessment by Mechanism of Action321
  Assessment by Route of Administration332
  Assessment by Molecule Type352
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Companies Involved in Therapeutics Development3727
  Abeome Corporation371
  Alnylam Pharmaceuticals, Inc.381
  AlphaMab Co., Ltd391
  AstraZeneca Plc401
  Aurigene Discovery Technologies Limited411
  BeiGene, Ltd.421
  Bristol-Myers Squibb Company431
  CytomX Therapeutics, Inc.441
  Eli Lilly and Company451
  F. Hoffmann-La Roche Ltd.461
  Genosco471
  ImmunoCellular Therapeutics, Ltd.481
  Immunocore Limited491
  IO Biotech ApS501
  Kadmon Corporation, LLC511
  MedImmune, LLC522
  Merck KGaA541
  Novartis AG551
  PsiOxus Therapeutics Limited561
  Regeneron Pharmaceuticals, Inc.571
  Shanghai Henlius Biotech Co., Ltd.581
  Sorrento Therapeutics, Inc.591
  Sutro Biopharma, Inc.601
  Theravectys SA611
  Tikcro Technologies, Ltd.621
  ViiV Healthcare Limited631
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Drug Profiles6475
  ALN-PDL Drug Profile641
  Antibody to Inhibit PD-L1 for Oncology Drug Profile651
  atezolizumab Drug Profile6611
  AUPM-327 Drug Profile771
  avelumab Drug Profile785
  Biologic to Inhibit PD-L1 for Immunology Drug Profile831
  BMS-936559 Drug Profile843
  CA-170 Drug Profile872
  CBA-0710 Drug Profile891
  CX-072 Drug Profile901
  dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide Drug Profile911
  durvalumab Drug Profile929
  durvalumab + gefitinib Drug Profile1011
  durvalumab + IMCgp-100 + tremelimumab Drug Profile1021
  durvalumab + MEDI-0680 Drug Profile1031
  durvalumab + MEDI-6383 Drug Profile1041
  durvalumab + MEDI-9447 Drug Profile1051
  durvalumab + monalizumab Drug Profile1061
  durvalumab + tremelimumab Drug Profile1073
  GNS-1480 Drug Profile1101
  HLX-10 Drug Profile1111
  HLX-20 Drug Profile1121
  IO-103 Drug Profile1131
  KD-033 Drug Profile1141
  KN-035 Drug Profile1151
  LY-3300054 Drug Profile1161
  Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile1171
  Monoclonal Antibodies to Inhibit PD-L1 for Oncology Drug Profile1181
  Monoclonal Antibodies to Inhibit PDL1 for Oncology Drug Profile1191
  Monoclonal Antibodies to Inhibit PDL1 for Oncology Drug Profile1201
  Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors Drug Profile1211
  Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile1221
  Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile1231
  Monoclonal Antibody to Inhibit PD-L1 for Oncology Drug Profile1241
  Monoclonal Antibody to Inhibit PDL-1 for Influenza Drug Profile1251
  Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology Drug Profile1261
  MSB-002 Drug Profile1271
  Oncolytic Viruses to Inhibit PDL1 for Solid Tumors Drug Profile1281
  Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology Drug Profile1291
  STIA-1011 Drug Profile1301
  STIA-1012 Drug Profile1311
  STIA-1014 Drug Profile1321
  STIA-1015 Drug Profile1331
  Synthetic Peptide 1 to Inhibit PD-L1 for Oncology Drug Profile1341
  Synthetic Peptide 2 to Inhibit PDL1 for Oncology Drug Profile1351
  Vaccine to Target CD274 and CD279 for Bladder Cancer Drug Profile1361
  Vaccine to Target CD274 and CD279 for Colorectal Cancer Drug Profile1371
  Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma Drug Profile1381
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Dormant Projects1391
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Discontinued Products1401
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Featured News &Press Releases14116
  Jun 06, 2016: ASCO 2016: Pivotal Avelumab Study Shows Positive Results In Metastatic Merkel Cell Carcinoma1411
  Jun 05, 2016: New Drug "Retrains" Immune System to Fight Aggressive Bladder Cancer1421
  Jun 05, 2016: Roche's cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer1432
  Jun 05, 2016: Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer1451
  Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints1451
  May 19, 2016: Aurora Diagnostics to Offer PD-L1 Tissue Assay for TECENTRIQ (atezolizumab)1461
  May 19, 2016: New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer1471
  May 18, 2016: FDA Grants Genentech s Cancer Immunotherapy TECENTRIQ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer1471
  May 18, 2016: Merck And Pfizer To Present Avelumab Data In Seven Different Cancers At ASCO Annual Meeting1483
  Apr 14, 2016: Kadmon to Present Preclinical Data Demonstrating that its Novel Immuno-Oncology Compound Achieves Long-Lasting and Persistent Antitumor Immunity1511
  Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting1511
  Apr 10, 2016: FDA Grants Priority Review for Genentech s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer1521
  Apr 06, 2016: Ludwig Cancer Research And The Cancer Research Institute Initiate Clinical Trial Of A Novel Combination Immunotherapy For Ovarian Cancer1531
  Apr 05, 2016: Merck And Pfizer Announce First Patient Treated In Phase III Combination Study With Avelumab And INLYTA In Renal Cell Carcinoma1541
  Mar 15, 2016: Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer1552
Appendix1572
  Methodology1571
  Coverage1571
  Secondary Research1571
  Primary Research1571
  Expert Panel Validation1571
  Contact Us1571
  Disclaimer1581

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Programmed-Cell-Death-1-Ligand-1-PD-L1-or-B7-Homolog-1-or-B7-H1-or-CD274-Pipeline-Review-H1-2016-2088-16012>
  
APA:
Global Markets Direct - Market Research. (2016). Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Programmed-Cell-Death-1-Ligand-1-PD-L1-or-B7-Homolog-1-or-B7-H1-or-CD274-Pipeline-Review-H1-2016-2088-16012>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.